CTH120

DRUG2 trials

Sponsors

Connecta Therapeutics, S.L.

Conditions

Fragile X SyndromeFragile X Syndrome (FXS)

Phase 1

CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction

CompletedNCT06480968

Connecta Therapeutics, S.L.Fragile X Syndrome

Start: 2023-06-23End: 2024-11-11Updated: 2025-01-23

Phase 2

Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome

RecruitingNCT07654114

Connecta Therapeutics, S.L.Fragile X Syndrome, Fragile X Syndrome (FXS)

Start: 2026-05-21End: 2027-05-01Target: 30Updated: 2026-07-17